About this trial
Prevention of postoperative pain is essential for the recovery of esophageal surgery. Epidural analgesia is a traditional and standard perioperative pain management for these patients. Beneficials of epidural analgesia have been widely established. However, there are still several potential disadvantages such as perioperative hypotension, failure of administration, rare but serious neurological complications. Ultrasound-guided regional nerve block has become a widely used technique due to its low degree of trauma and precise target of action. In combined with liposome bupivacaine (LB), a new long-acting local anesthetic, was proven to have a maximum duration of 72 hours, thus improving postoperative analgesia, reducing opioid consumption, and enhancing patient satisfaction. The aim of this study was to evaluate the efficacy of TPVB liposomal bupivacaine (LB) or plane bupivacaine (SB) for Overall Benefit of Analgesic Score (OBAS) after esophageal surgery.
Eligibility criteria
Qualifiers
American Society of Anesthesiologist physical status I-III;
Scheduled elective thoracoscopic esophagectomy(three-incision approach);
Approved participation before study.
Disqualifiers
Patients with contraindications for local nerve block such as spinal anatomic structure abnormality or local infection of puncture area;
Anergic to medications used in this study;
Patient have chronic pain;
Patient receiving anticoagulants, opioids or have a history of narcotic abuse or alcohol abuse;
Trial design
Treatments tested in this trial
- Liposomal bupivacaine
- Bupivacaine Hydrochloride